Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 925 of 2529 entries
View as:

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02205398 Org: User:
Start: 07/28/14 End: 01/20/17 Due: 01/20/18

Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT01601470 Org: User:
Start: 09/30/12 End: 01/31/13 Due: 01/31/14

Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL)

Phase: N/A Priority: Normal
NCT ID: NCT05366257 Org: User:
Start: 08/17/20 End: 05/10/21 Due: 05/10/22

Study to Assess Iron Chelation Therapy in Patients With Chronic Iron Overload

Phase: N/A Priority: Normal
NCT ID: NCT05440487 Org: User:
Start: 09/15/15 End: 10/29/21 Due: 10/29/22

Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01155713 Org: User:
Start: 07/31/10 End: 11/30/13 Due: 11/30/14

Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab

Phase: N/A Priority: Normal
NCT ID: NCT02559622 Org: User:
Start: 04/30/14 End: 04/30/16 Due: 04/30/17

16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis

Phase: N/A Priority: Normal
NCT ID: NCT01358175 Org: User:
Start: 10/31/11 End: 12/31/14 Due: 12/31/15

Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events

Phase: N/A Priority: Normal
NCT ID: NCT00346242 Org: User:
Start: 03/31/04 End: - Due: -

Safety of CHIR-258 (TKI258) in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01270906 Org: User:
Start: 12/31/03 End: - Due: -

Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00102466 Org: User:
Start: 01/31/05 End: 01/31/09 Due: 01/31/10

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.

Phase: N/A Priority: Normal
NCT ID: NCT01844765 Org: User:
Start: 08/20/13 End: 08/28/20 Due: 08/28/21

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

Phase: N/A Priority: Normal
NCT ID: NCT06711887 Org: User:
Start: 05/21/25 End: 07/28/32 Due: 07/28/33

Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib

Phase: N/A Priority: Normal
NCT ID: NCT00756509 Org: User:
Start: 08/29/08 End: 12/18/24 Due: 12/18/25

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (SA-AKI)

Phase: N/A Priority: Normal
NCT ID: NCT05996835 Org: User:
Start: 01/18/24 End: 02/20/26 Due: 02/20/27

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

Phase: N/A Priority: Normal
NCT ID: NCT01032915 Org: User:
Start: 02/28/10 End: 06/30/11 Due: 06/30/12

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Phase: N/A Priority: Normal
NCT ID: NCT00110266 Org: User:
Start: 07/25/05 End: 03/28/08 Due: 03/28/09

Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis

Phase: N/A Priority: Normal
NCT ID: NCT02896127 Org: User:
Start: 10/18/16 End: 03/19/19 Due: 03/19/20

Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice

Phase: N/A Priority: Normal
NCT ID: NCT05112835 Org: User:
Start: 11/19/21 End: 09/08/22 Due: 09/08/23

The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada

Phase: N/A Priority: Normal
NCT ID: NCT01105507 Org: User:
Start: 08/31/10 End: 05/12/12 Due: 05/12/13

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Phase: N/A Priority: Normal
NCT ID: NCT01595009 Org: User:
Start: 04/27/11 End: 08/09/16 Due: 08/09/17

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Phase: N/A Priority: Normal
NCT ID: NCT02460224 Org: User:
Start: 06/17/15 End: 12/31/20 Due: 12/31/21

Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies

Phase: N/A Priority: Normal
NCT ID: NCT04648930 Org: User:
Start: 01/27/21 End: 11/03/22 Due: 11/03/23

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01857193 Org: User:
Start: 09/06/13 End: 04/16/20 Due: 04/16/21

Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients

Phase: N/A Priority: Normal
NCT ID: NCT01646671 Org: User:
Start: 07/31/12 End: 02/28/13 Due: 02/28/14

Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01356381 Org: User:
Start: 04/30/11 End: 08/31/13 Due: 08/31/14